Galapagos NV (GLPGF)

Market Cap	1.93B +12.2%
Revenue (ttm)	1.31B +303.5%
Net Income	376.76M +333.1%
EPS	5.72 +334.8%
Shares Out	n/a
PE Ratio	5.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43
Average Volume	725
Open	33.27
Previous Close	34.00
Day's Range	33.27 - 33.27
52-Week Range	22.39 - 34.00
Beta	0.10
RSI	53.17
Earnings Date	Mar 26, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 704
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLPGF

Financial Performance

In 2025, Galapagos NV's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR